Dr Hilary Cass has said she is "absolutely convinced that more children will be harmed if we don't do the trial than if we do," pressing publicly for a clinical trial of puberty-suppressing hormones to proceed despite the blanket ban her own review precipitated.

The statement, reported by the BBC on 22 June 2026, marks a significant moment of tension between the policy trajectory that followed the Cass Review and the clinical judgment of its author. The review, commissioned as an independent examination of NHS gender identity services, found "remarkably weak" evidence on puberty blockers and concluded that the rationale for early puberty suppression was unclear. Its final report, published on 10 April 2024, contained 32 recommendations spanning all aspects of service provision.

One of those recommendations was specific: puberty-suppressing hormones should be prescribed to under-18s only within a research protocol. The NHS had already stopped routine prescriptions in March 2024, ahead of the final report's publication. The government subsequently moved to codify that restriction — and in December 2024, ministers announced the ban would be made indefinite, acting on advice from a panel of clinical experts.

The gap between recommendation and policy

There is a material difference between what Cass recommended and what policy now reflects. Her review called for a tightly governed research protocol — not a permanent prohibition. The indefinite ban, as framed by the government's December 2024 announcement, forecloses the research pathway that the review explicitly endorsed as the only defensible route to generating better evidence.

That gap is precisely what Cass is now drawing attention to. Her position is not a reversal of her review's findings. It is, if anything, a defence of one of its core planks: that the absence of robust evidence demands evidence generation, not evidence avoidance. The clinical trial she is advocating for would, in her framing, be the mechanism through which the review's own epistemic concerns get resolved.

The government's October 2025 consultation outcome confirmed the administration's reading of the evidence base as insufficient to justify prescribing outside a research context — a position that aligns with Cass's methodology but not, it now appears, with her view of what should follow from it.

What this means for the policy landscape

For those working across health policy, equalities, and the devolved administrations, the practical question is whether Cass's public intervention shifts the political calculus. Gender services are a devolved matter in Scotland, Wales, and Northern Ireland, and Holyrood, the Senedd, and Stormont have each navigated their own responses to the review's recommendations. The indefinite ban in England does not automatically apply across the UK's four nations, though prescription practices have shifted NHS-wide.

Westminster will now face renewed pressure to distinguish between a blanket prohibition and the structured research access the review actually proposed. Those are not the same policy. The first ends the question. The second — a properly governed randomised controlled trial with appropriate ethical oversight — is what the Cass Review's own logic demands: if the evidence is weak, the answer is to produce better evidence under controlled conditions, not to lock in uncertainty indefinitely.

Whether ministers treat Cass's intervention as a technical clarification or a political inconvenience will depend partly on the trial's current status — which the verified facts do not confirm — and partly on how much political weight the government still attaches to the review's authority on other aspects of transgender healthcare provision.

What is not in doubt is that Cass has now placed herself in an uncomfortable position relative to the policy she enabled: advocating for clinical access — however conditional — at the same moment the government uses her review as the basis for denying it.